Cstone announces the inclusion of CEJLI ® (Sugemalimab) as a combined first line for NSCLC in ESMO guidelines

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.